Pupil expansion devices are an essential element of cataract surgery in cases of non-dilating pupils. An adequately sized capsulorrhexis with an adequate and appropriate exposure of the surgical space ensures the ease of surgery. Without the use of a proper pupil expansion device, a small pupil may cause complications such as sphincter tears, intraoperative bleeding, zonular dialysis and, in extreme cases with prolonged struggle, possibly even posterior capsular rent or nucleus drop. Prolonged surgical time and increased maneuvering may result in postoperative complications such as striate keratopathy, uveitis, secondary glaucoma, floppy iris, torn iris, atrophic iris, irregular pupil, endophthalmitis or cystoid macular edema, all resulting in a suboptimal surgical outcome and an unhappy patient.Currently available devices are designed to be placed either totally intraocularly (rings) or partially externally with the intraocular extension of the device holding back the pupil retracting the iris tissue (iris hooks, Assia pupil expander). The I-Ring is a new pupil expansion device from Beaver-Visitec that is designed to safely expand the iris tissue and enhance the surgeon’s field of view.
Surgeon prefers fourth-generation fluoroquinolones as prophylaxis for cataract surgery
WAIKOLOA, Hawaii — At Hawaiian Eye, James P. McCulley, MD, FACS, FRCOphth, gives reasons for his off-label use of fourth-generation fluoroquinolones as prophylaxis before, during and after cataract surgery.
Choroidal detachment, hypotony may be common after 23-gauge PPV
Choroidal detachment and hypotony are common after 23-gauge pars plana vitrectomy, and most complications may be associated with the use of fluid tamponade, according to a study.The prospective observational study compared the clinical features of 49 e…
Abbott reports $20.4 billion in 2015 worldwide sales
Abbott reported $20.4 billion in worldwide sales for 2015, a 9.1% increase on an operational basis and a 0.8% increase on a reported basis compared with 2014, according to a press release. Worldwide sales were reported at $5.2 billion in the fourth qua…
Aerie Pharmaceuticals executive gives update on clinical trials in 2016
SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum here, Tom Mitro, president and COO of Aerie Pharmaceuticals, gives an update on the progress in clinical trials for both Rhopressa and Roclatan.
ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 8:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation will be accessible on the company’s webs